Advanced search
Publication Cover
Future Neurology Volume 2, 2007 - Issue 4
Submit an article Journal homepage
83
Views
0
CrossRef citations to date
0
Altmetric
Review

Bipolar disorder pharmacotherapy

Timothey C Denkoa Assistant Professor of Psychiatry Mood Disorders Research & Treatment Program, University of Pittsburgh, School of Medicine, Department of Psychiatry, 3811 O‘Hara Street, Pittsburgh, PA15213, USA. [email protected]
&
Michael E Thaseb Professor of Psychiatry Mood Disorders Research & Treatment Program University of Pennsylvania, School of Medicine, Department of Psychiatry, 3535 Market Street, Suite 670, PA, USA, and, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104-3309, USA. [email protected]
Pages 441-450 | Published online: 20 Jun 2007

Bibliography

  • Swann AC , BowdenCL, CalabreseJRet al.: Pattern of response to divalpoex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology26(4), 530–536 (2002).
  • Goodwin FK , FiremanB, SimonGEet al.: Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA290(11), 1467–1473 (2003)
  • Bowden CL , CalabreseJR, McElroySLet al.: A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar 1 disorder. Arch. Gen. Psychiatry57(5), 481–489 (2000).
  • Gyulai L , BowdenCL, McElroySLet al.: Maintenance efficacy of divalpoex in the prevention of bipolar depression. Neuropsychopharmacology28(7), 1374–1382 (2003).
  • Physicians‘ Desk Reference: Thomson Healthcare. 434 (2006).
  • Allen MH , HirschfeldRM, WozniakPJ, BakerJD, BowdenCL: Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania.Am. J. Psychiatry163(2), 272–275 (2006).
  • Weisler RH , HirschfeldR, CutlerAJet al.: Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs20(3), 219–231 (2006).
  • Kushner SF , KhanA, LaneR, OlsonWH: Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials.Bipolar Disord.8(1), 15–27 (2006).
  • Chengappa KN , RathoreD, LevineJet al.: Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord.1(1), 42–53 (1999).
  • Pande AC , CrockattJG, JanneyCA, Werth JL, Tsaroucha G: Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord.2(3 Pt 2), 249–255 (2000).
  • Frye MA , KetterTA, KimbrellTAet al.: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacology20(6), 607–614 (2000).
  • Perlis RH , WelgeJA, VornikLA, Hirschfeld RM, Keck PE Jr: Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J. Clin. Psychiatry67(4), 509–516 (2006).
  • Bowden CL , BruggerAM, SwannACet al.: Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group (see comment) (erratum appears in JAMA, 271[23], 1830 [1994]). JAMA271(12), 918–294 (1994).
  • Yatham LN , PaulssonB, MullenJ, Vagero AM: Quetiapine versus placebo in combination with lithium of divalproex for the treatment of bipolar mania. J. Clin. Psychopharmacology24(6), 599–606 (2004).
  • Yatham LN , GrossmanF, AugustynsI, Vieta E, Ravindran A: Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br. J. Psychiatry182, 141–147 (2003).
  • Tohen M , ChengappaKN, SuppesTet al.: Efficacy of olanzapine in combination with valproate of lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry59(1), 62–69 (2002).
  • Sachs G , SanchezR, MarcusRet al.: Aripiprazole in the treatment of acure manic or mixed episodes in patients with bipolar 1 disorder: a 3-week placebo-controlled study. J. Psychopharm.20(4), 536–546 (2006).
  • Keck PE Jr, Calabrese JR, McQuade RD et al.: A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry67(4), 626–637 (2006).
  • Thase ME : Bipolar depression: issues in diagnosis and treatment.Harv. Rev. Psychiatry13(5), 257–271 (2005).
  • Post RM , AltshulerLL, LeverichGSet al.: Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion, and sertraline. Br. J. Psychiatry189, 124–131 (2006).
  • Leverich GS , AltshulerLL, FryeMAet al.: Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am. J. Psychiatry163(2), 232–239 (2006).
  • Sachs GS , NierenbergAA, CalabreseJRet al.: Effectiveness of adjunctive antidepressant treatment for bipolar depression: a double-blind placebo controlled study. N. Engl. J. Med.356(17), 1711–1722 (2007).
  • Vieta E , Martinez-AranA, GoikoleaJMet al.: A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J. Clin. Psychiatry63(6), 508–512 (2002).
  • Gijsman HJ , GeddesJR, RendellJM Nolaen WA, Goodwin GM: Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry.161(9), 1537–1547 (2004).
  • Altshuler L , SuppesT, BlackDet al.: Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up (see comment). Am. J. Psychiatry160(7), 1252–1262 (2003).
  • Tohen M , VietaE, CalabreseJet al.: Efficacy of olanzapine and olanzapine–fluoxetine combination in the treatment of bipolar I depression (see comment) (erratum appears in Arch. Gen. Psychiatry 61[2], 176 [2004]). Arch. Gen. Psychiatry60(11), 1079–1088 (2003).
  • Brown EB , McElroySL, KeckPEet al.: A 7-week, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar 1 depression. J. Clin. Psychiatry67(7), 1025–1033 (2006).
  • Calabrese JR , KeckPE Jr, Macfadden W et al.: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry162(7), 1351–1360 (2005).
  • Thase ME , MacfaddenW, WeislerRHet al.: Efficacy of quetiapine monotherapy in the treatment of bipolar 1 and bipolar 2 depression – a double-blind, placebo-controlled study (The Bolder 2 study). J. Clin. Psychopharmacology26(6), 600–609 (2006).
  • Bowden CL , CalabreaseJR, SachsGet al.: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar 1 disorder. Arch. Gen. Psychiatry60(4), 392–400 (2003).
  • Goodwin GM , BowdenCL, CalabreseJRet al.: A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J. Clin. Psychiatry65(3), 432–441 (2004).
  • Tohen M , CalabreseJR, SachsGSet al.: Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am. J. Psychiatry163(2), 247–256 (2006).
  • Tohen M , GreilW, CalabreseJRet al.: Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am. J. Psychiatry162(7), 1281–1290 (2005).
  • Baldessarini RJ , TondoL, HennenJ, VigueraAC: Is lithium still worth using? An update of selected recent research.Harv. Rev. Psychiatry10(2), 59–75 (2002).
  • Baldessarini RJ , TondoL, DavisP, Pompili M, Goodwin FK, Hennen J: Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord.8(5 Pt 2), 625–639 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.